WEKO3
アイテム
2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)
http://hdl.handle.net/10191/48382
http://hdl.handle.net/10191/483821621ca79-105e-49ee-9231-02ecc9928795
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-11-09 | |||||
タイトル | ||||||
タイトル | 2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Small cell lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Dose intensive chemotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Granulocyte Colony-Stimulating Factor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hematopoietic Stem Cell Transplantation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Leukapheresis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 小細胞肺癌 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 高用量化学療法 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 顆粒球コロニー刺激因子 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 造血幹細胞移植 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 幹細胞採取 | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | Phase I Dose Escalation Study of Multicyclic, Dose-Intensive Chemotherapy with Peripheral Blood Stem Cell Support for Small Cell Lung Cancer | |||||
著者 |
吉澤, 弘久
× 吉澤, 弘久× 松本, 尚也× 望月, 博史× 栗山, 英之× 各務, 博× 鈴木, 栄一× 下条, 文武 |
|||||
著者別名 | ||||||
識別子 | 94977 | |||||
識別子Scheme | WEKO | |||||
姓名 | Yoshizawa, Hirohisa | |||||
著者別名 | ||||||
識別子 | 94978 | |||||
識別子Scheme | WEKO | |||||
姓名 | Matsumoto, Naoya | |||||
著者別名 | ||||||
識別子 | 94979 | |||||
識別子Scheme | WEKO | |||||
姓名 | Mochizuki, Hiroshi | |||||
著者別名 | ||||||
識別子 | 94980 | |||||
識別子Scheme | WEKO | |||||
姓名 | Kuriyama, Hideyuki | |||||
著者別名 | ||||||
識別子 | 94981 | |||||
識別子Scheme | WEKO | |||||
姓名 | Kagamu, Hiroshi | |||||
著者別名 | ||||||
識別子 | 94982 | |||||
識別子Scheme | WEKO | |||||
姓名 | Suzuki, Eiichi | |||||
著者別名 | ||||||
識別子 | 94983 | |||||
識別子Scheme | WEKO | |||||
姓名 | Gejyo, Fumitake | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion of peripheral blood stem-cells (PBSCs) was conducted to determine the maximum-tolerated dose (MTD) of ICE. Twenty-seven patients with SCLC (LD : 9, ED : 18) were treated with ifosfamide (3000-9000mg/m^2, 24-hour-infusion), carboplatin (300-400mg/m^2), and etoposide (300mg/m^2) followed by subcutaneous injection of filgrastim (75μg/day) through day 4 to the day of PBSC collection. PBSC were harvested when the WBC count reached ≧5×10^9/L. The leukapheresis product was cryopreserved and reinfused on day 4 of the next cycle, which was started 48 hours after the last PBSC collection. The ifosfamide dose was escalated as follows : 3000mg/m^2 (level 1), 5000mg/m^2 (level 2), 7000mg/m^2 (level 3), 9000mg/m^2 (level 4). Patients with LD were treated with concurrent radiotherapy at 1.5 Gy twice daily for the initial 3 weeks to a total dose of 45Gy and MTD, defined separately. Patients were evaluated for hematologic and non-hematologic toxicity, actual dose intensities, as well as response to the therapy. The maximum-tolerated dose (MTD) was defined as the dose level at which the level produced more than 5 days of grade 4 myelosuppression or non-hematologic toxicity greater than grade 3 in two thirds of the patients. For ED cases, MTD was level 4 and the recommended dose of ifosfamide was 7000mg/m^2. For LD cases, the recommended dose of ifosfamide was 5000mg/m^2. The dose limiting toxicity of multicyclic ICE was hematologic toxicity and CNS toxicity which manifested as ataxia. Tumor responses were seen in all patients, with 14 patients showing a complete response. The actual total dose-intensity at the recommended dose level was 2.2 and 1.74, for ED and LD, respectively, compared with previously reported ICE regimens. PBSC support for dose-intensive ICE regimen permitted dose escalation of ifosfamide with a mean interval of 16-17 days. We conclude this regimen is well tolerated, with acceptable hematological and non-hematological toxicity. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 115, 号 9, p. 432-437, 発行日 2001-09 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
著者版フラグ | ||||||
値 | publisher |